Mitchell Finkel

Mitchell Finkel supports clients with evidence-based research and analysis that spans healthcare sectors and stakeholders.

With a background in health policy and clinical research, he contributes to the development of client analysis and insights.

Mitchell’s background in health policy, government affairs, and clinical research includes varied research experiences. His clinical research included the administration of a large-scale, cross-sectional survey and assisting in other randomized controlled studies and cohort design studies to assess the effectiveness of the GW Emergency Health Services Department’s interventions. At Todd Strategy, he researched and summarized regulatory and legislative issues affecting the pharmaceutical and bio-tech sectors. Additionally, as a participant in a community hospital rotation program, he gained an understanding of the clinical setting for a variety of medical specialties and the hospital environment, including policies and patient advocacy.

Mitchell has a BS in Public Health from George Washington University.

Authored Content

As the novel coronavirus disease (COVID-19) continues to change daily life, concerns about the impact on global supply chains and possible drug shortages have increased. Additionally, changes to FDA processes may limit its ability to perform essential drug related activities.

New analysis from Avalere finds that states currently covering non-mandatory adult populations who choose to participate in the Healthy Adult Opportunity (HAO) initiative may need to generate up to 8% in Medicaid savings to keep spending below new capped funding levels.